← FDA DRUG APPROVALS

FDA ANDA · ANDA206210

TOPIRAMATE

Sponsor: ACTAVIS LABS FL

APPLICATION
ANDA206210
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-10
LATEST ACTION
2025-10-23
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

TOPIRAMATEPrescription
TOPIRAMATE 200MG · CAPSULE, EXTENDED RELEASE · ORAL
TOPIRAMATEPrescription
TOPIRAMATE 50MG · CAPSULE, EXTENDED RELEASE · ORAL
TOPIRAMATEPrescription
TOPIRAMATE 100MG · CAPSULE, EXTENDED RELEASE · ORAL
TOPIRAMATEPrescription
TOPIRAMATE 25MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2025-10-23Labeling · Supplement 5 · standardAP
2025-10-23Labeling · Supplement 2 · standardAP
2023-03-10UNKNOWN · Original · standardAP
2023-03-10UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →